

ORIGINAL

PATENT JOG

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of: Alonso-Alija, et al.

Group No.:1626

Application No.: 10/088,060

Examiner: Saeed, Kamal A.

Filed:

06/02/2002

For: Novel Derivatives of Dicarboxylic Acid Having Pharmaceutical Properties

CERTIFICATION OF MAILING UNDER 37 C.F.R. 1.8(a)

I hereby certify that this correspondence and any papers referred to as attached are being deposited, on the date shown below, with the United States Postal Service, with sufficient postage, as first class mail in an envelope addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Date: June 18,2004

Eugenia Boshnack

Assistant Commissioner for Patents Washington, D.C. 22313

TRANSMITTAL OF INFORMATION DISCLOSURE STATEMENT BEFORE MAILING DATE OF EITHER A FINAL ACTION OR NOTICE OF ALLOWANCE (37 C.F.R. § 1.97(c))

TIME OF TRANSMITTAL OF ACCOMPANYING INFORMATION DISCLOSURE STATEMENT

- The information disclosure statement transmitted herewith is being filed after three months of the filing date of this national application or the date of entry of the national stage as set forth in Section 1.491 in an international application or after the mailing date of the first Office action on the merits, whichever event occurred last but before the mailing date of either
 - (1) a final action under section 1.113 or
 - (2) a notice of allowance under section 1.311

whichever occurs first.

FEE

2. Accompanying this transmittal is the fee for submission of an information disclosure statement under § 1.97(c). (\$180.00)

06/24/2004 GWORDOF1 00000056 133372 10088060

01 FC:1806

180.00 DA



ORIGINAL

Attorney Docket No. Le A 33 878

FEE PAYMENT

3. Applicant elects the option to pay the fee set forth in 37 C.F.R. § 1.17(p) for submission of an information disclosure statement under § 1.97(c) (\$180.00).

Fee due \$ 180.00

METHOD OF PAYMENT OF FEE

4. Please charge Account No. 13-3372 in the amount of \$ 180.00. The Commissioner is also authorized to charge any fees that may have been overlooked but that are required to Deposit Account 13-3372. Additionally, please credit any overpayment to the same account.

Respectfully submitted,

Reg. No. 31,018

Telephone: (203) 812-2712

Date: 17 June '04

William F. Gray

Attorney for Applicant(s)

Bayer Corporation

400 Morgan Lane

West Haven, CT 06516

Form PTC (Modified				U.S. Department of Commerce Patent and Trademark Office					Serial No.	erial No. Art Unit		Filing Date		Atty. Docket No	
(INIOGINICA))		ratent and Trademark Office						10/088,060 1626		06/02/2002		Le A 33 878		
INFORMATION DISCLOSURE CITATION									Applicant(s)						
ENFORMATION DISCLOSURE CITATION									Alonso-Alija, et al.						
JUN 2 1 7004 E															
		*/		DOCUMENT NO.					DATE	NAME	CLASS	SUB-		FILING DATE	
Piren	· -2kr	_ _							(MM/DD/YY)		l	CLASS	IF APPROPRIATE		
	+		 	 	 	-	 '	-			+				
			ـــــ	 	↓	—	├ —'	 	ļ			_			
							'								
											1				
			\vdash		 	 		 	-		+	 	 		
	++		-	-	 	-	 '				 	ļ			
		<u> </u>	<u> </u>	<u> </u>	<u> </u>	<u> </u>	<u> </u>	<u> </u>							
				'											
						J	FORE	IGN	PATENT DO	CUMENTS			•		
			DOCUMENT NO.						DATE	COUNTRY	PRIMARY	SUB-	TRANSLATION		
*									(DD/MM/YY)		CLASS	CLASS	YES	NO	
														 	
	<u></u>		ОТН	ER R	EFEI	RENC	ES (I	nelu	ding Author.	Γitle, Date, Per	tinent Pages	etc.)		1	
-	R1	Stas	sch, et	t al., "I	NO- a	ınd H	aem-in	ndeper	ndent Activation	of Soluble Guan	ylyl Cyclase:	Molecular	Basis and	Cardio	
	R2	We	ber, et	t al., "T	The Ef	fect of	f Perox			le." Brit. J. of Ph				Bio. &	
			Weber, et al., "The Effect of Peroxynitrate on the Catalytic Activity of Soluble Guanylyl Cyclase.," Free Rad. Bio. & Med. 31, 1360-1367, (2001). Pryor, et al., "The Chemistry of Peroxynitrate: A product from the Reaction of Nitric Oxide with Superoxide", Am.												
	R3								nitrate: A produc	t from the Reaction	on of Nitric C	xide with	Superoxide'	", Am .	
	R4		J. Physiol, <u>268</u> , L699-L722,(1995). Harrison, M.D. et al., "Endothelial Function and Oxidant Stress", Clin. Cardiol., <u>20</u> , II-11-17, (1997).												
	R5		Stasch, et al., "Pharmacological Actions of a Novel NO-Independent Guanylyl Cyclase Stimulator, Bay 41-8543: <i>in vitro</i> Studies." Brit. J. of Pharma. <u>135</u> , 333-343, (2002).												
	R6									diazolo[4,3-a]quir cology, <u>50,</u> 1-5, (1		as a Hem	e-Site Inhib	oitor of	
	R7	Sch	ımidt,	et al.,	, "Me	chanis	sms of			endent Activation		Guanylyl	Cyclase,"	Eur. J.	
	R8			ol. <u>468,</u> te, et al				ctive	Inhibition of Nit	ric Oxide-Sensitiv	ve Guanylyl C	yclase by	<i>H</i> -		
		[1,2	2,4]Ox	adiazo	olo[4,3-	-a] qui	inoxali	n-1-or	ne", Mol. Pharma	a, <u>48</u> 184-188, (19	995).				
	R9		Schmidt, et al., "Identification of Residues Crucially Involved in the Binding of the Heme Moiety of Soluble Guanylate Cyclase", J. Biol. Chem. (in press, 2003).												
	R10						<u>02,</u> II-3								
EXAMINE	ER.	<u> —</u>							DATE	CONSIDERED					
										30.10 . 22.122					
									is in conformance tion to applicant.	with MPEP 609. D	raw line throug	h citation if	not in confort	mance	